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Abstract. The junctional adhesion molecule B (JAM-B) is a 
multifunctional transmembrane protein, which belongs to the 
immunoglobulin superfamily (IgSF). JAM-B is localized to 
cell-cell contacts and enriched at cell junctions in epithelial 
and endothelial cells, as well as on the surface of erythro-
cytes, leukocytes, and platelets. Recent research in this field 
has shown that JAM-B plays an important role in numerous 
cellular processes, such as tight junction assembly, spermato-
genesis, regulation of paracellular permeability, leukocytic 
transmigration, angiogenesis, tumor metastasis and cell prolif-
eration. This study provides a new research direction for the 
diagnosis and treatment of relevant diseases. In this review, we 
briefly focus on what is currently known about the structure, 
function, and mechanism of JAM-B, with particular emphasis 
on cancer.
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1. Introduction
Tight junctions (TJs) are the apical junctional complex in 
epithelial and endothelial cells (1). TJs play a key role in 
maintaining distinct tissue spaces and regulating paracellular 
flux of small molecules and inflammatory cells, as well as 
promoting bi-directional signaling between the intracellular 
and extracellular compartments (2-4). Furthermore, tumor 
differentiation is related to the reduction of TJs, and tumor 
cells must overcome the frontline structures of TJs in order to 
successfully metastasize (5-7).
The JAM family belongs to the immunoglobulin subfamily 
involved in the formation of TJ in most cell types, including 
leukocytes, platelets, endothelial and epithelial cells (2,8-10). 
JAMs have been reported to regulate epithelial TJ assembly, 
and interact in both a homo- and heterotypic fashion, as 
well as with integrins (3,11,12). The JAM family comprises 
five members, namely JAM-A, JAM-B, JAM-C, JAM-4, and 
JAM-like (13-16). There are many differences between JAM-B 
and the other JAM family members. This review will highlight 
that which is currently known about the structure, function, 
and mechanisms of action of JAM-B and potential areas for 
future study.
2. Structure of the JAM family
Members of the JAM family are type I transmembrane glyco-
proteins consisting of a short N-terminal signal peptide, two 
immunoglobulin-like domains, one transmembrane domain 
and one cytoplasmic tail of variable length containing a 
C-terminal PDZ-domain domain (4,17-20). In the case of 
JAM-A, the sequence was described by multiple investiga-
tors as two C2-type domains in mouse (10) and two V-type 
domains in human (2). However, the Ig-like domains of JAM-B 
and JAM-C are composed of V type and C2 type (18) (Fig. 1). 
A J-like sequence is contained in the V domain and an extra 
disulfide bridge between cysteines involved incorporated in 
the C2-type domain (19). 
Some studies have found that JAM-A has a three amino 
acid sequence (Val-Leu-Val) in the connection between the two 
Ig-like domains which causes the distal Ig-like domains to bend 
and bind to another three amino acid sequence (Arg-Leu-Glu) 
in the V type Ig-like domains and dimerise (20,21). A JAM-A 
dimer at the surface of cells may interact in a trans orientation 
with another dimer of JAM2 expressed by the adjacent cell, 
forming a tetramer. The successive JAM tetramer would be 
able to structure a zipper-like structure surrounding the cell at 
the apical cells border. It was found that JAM-B (Arg-Leu-Glu) 
The role of JAM-B in cancer and cancer metastasis (Review)
HUISHAN ZHAO1-4,  HEFEN YU1-3,  TRACEY A. MARTIN4,  XU TENG1-4  and  WEN G. JIANG2-4
1Department of Biochemistry and Molecular Biology, School of Basic Medicine, Capital Medical University, Beijing 100069; 
2Cancer Institute of Capital Medical University, Beijing 100069; 3Beijing Key Laboratory for Cancer Invasion 
and Metastasis Research, Beijing 100069, P.R. China; 4Cardiff-China Medical Research Collaborative, 
Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK
Received October 28, 2015;  Accepted December 8, 2015
DOI: 10.3892/or.2016.4773
Correspondence to: Professor Wen G. Jiang, Cardiff-China 
Medical Research Collaborative, Cardiff University School of 
Medicine, Heath Park, Cardiff CF14 4XN, UK
E-mail: jiangw@cf.ac.uk
Key words: tight junction, junctional adhesion molecule-B, tumor 
progression, JAM family proteins
ZHAO et al:  JAM-B AND CANCER2
and JAM-C (Arg-Ile-Glu) could form the same type of dimeri-
sation motifs as seen in JAM-A (19).
3. Expression profiles and subcellular localization
The JAM family exhibits different expression profiles and 
transcript level in various tissues, organs and tumors (Table I). 
Overall, as an important member of the TJ complex, JAMs 
are generally expressed in subsets of leukocytes, as well as 
in epithelial and endothelial cells (22,23). However, compared 
with JAM-A and JAM-C, JAM-B displays a restricted distri-
bution. It is expressed in the junctions of endothelial cells 
of different vessels, but mostly localizes in high endothelial 
venules (13,25).
Amongst different types of tumors, it is difficult to quan-
titatively analyze differences in the expression of the JAM 
family. Therefore, the differential expression of JAM-B in 
cancer and normal tissues must be compared in a similar 
tumor type. Multiple studies have shown that the expression of 
JAM-B shows significant differences when comparing normal 
and cancerous tissues with the data presented in Table II. 
4. Related signaling pathways
JAM receptor. As reported, classical JAMs, containing an 
intracellular PDZ binding domain which may act as an anchor 
for scaffolding adaptor proteins, can mediate cellular functions, 
embryonic development (26), junction assembly, spermato-
genesis, paracellular permeability, leukocytic transmigration, 
angiogenesis, tumor metastasis and cell proliferation through 
binding and interacting with receptors such as ligand and 
integrin (17,27-33). The heterodimeric transmembrane recep-
tors, the integrins, contain α- and β-subunits, which mediate 
cell-to-cell adhesive interactions.
Role of the receptor in JAM-B functions. There are several 
studies which report JAM-B interacting with JAM-C and 
the integrin α4β1, forming multimer interactions with 
integrin counter-receptors. JAM-B can interact with the inte-
grin α4β1, but this is dependent on the presence of JAM-C. 
In 1996, Butcher and Picker described integrin-mediated 
T-lymphocyte adhesion inflamed endothelium through 
VCAM-1 (34). However, whether the integrin could engage 
JAM-B and VCAM-1 simultaneously through different 
binding sites is still unclear. However, JAM-B and VCAM-1 
may interact with one another laterally and reinforce integrin 
through conformational changes (35). Other reports claim 
that on human circulating platelets, dendritic cells, NK cells, 
and subsets of T and B cells, JAM-C plays an extended role as 
the leukocyte counter receptor for JAM-B expressed on endo-
thelial cells (11,36-40). In 2009, Ludwig et al found that using 
a model of DNFB-induced contact hypersensitivity, JAM-B 
played a role in rolling and firm adhesion of T lymphocytes 
by interacting with α4β1 (41). However, a recent study 
proposed JAM-B to play an independent role in leukocyte 
transmigration. 
Functional epitopes in JAM-B proteins. JAM-B has been 
reported involved in many kinds of biological processes, for 
instance, leukocyte migration (39,42-44), spermatogenesis 
(45) and angiogenesis (46) through its interaction with JAM-C. 
Previous study has shown that blocking the interactions of 
Figure 1. The structure of JAM-A, -B and -C.
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JAM-B and -C can reduce monocyte numbers in the ablumenal 
compartment by increasing reverse transmigration rather than 
through reducing transmigration (47). 
The effect of JAM-B and JAM-C in leukocyte accumula-
tion during inflammation has also been monitored (39,43,48). 
For example, a study suggested anti-JAM-B and anti-JAM-C 
antibodies played a role of addition agent in blocking leuko-
cytes infiltration in the model of allergic contact dermatitis, 
indicating that the actions of JAM-B and -C are indispens-
able for development of cutaneous inflammation (50). 
Previous study has shown that blocking the interactions of 
JAM-B and -C can reduce monocyte numbers in the ablu-
menal compartment by increasing reverse transmigration 
rather than through reducing transmigration. Overall, the 
results indictate that the blocking of JAM-B/-C interactions 
decreased the number of monocytes in inflamed tissues owing 
to considerably increased level of reverse-transmigrated 
monocytes in the peripheral blood.
Signaling pathways. The cellular localization of JAMs is 
related to specific signals of the extracellular environment. 
Phosphorylation of the cytoplasmic tail of JAMs plays a 
key role in the mechanism of regulating the localization of 
JAMs. The classical JAM proteins all contain C-terminal 
PDZ-binding domains which can be modified by kinases and 
may facilitate the interaction with PDZ-containing proteins, 
such as TJ-associated cytoplasmic proteins AF6, PAR3, ZO1, 
CASK, MAGI and MUPP1 (15,50-54). In 2003, Ebnet et al 
showed that JAM-B and JAM-C could directly associate with 
PAR-3 through its first PDZ domain, and could also associate 
with protein ZO-1 in a PDZ domain-dependent manner (55). 
Recently, antibodies against murine JAM-B inhibited 
microvessel endothelial cell proliferation were demonstrated 
through in vitro endothelial network formation assays and 
ex vivo aortic rings. This research also showed that JAM-B 
can negatively regulate pro-angiogenic pathways and inhibit 
VEGF-induced ERK1/2 activation through integrin activation 
in MAPK pathway (56).
5. Multiple roles of JAM-B in cancer
Following the investigation of JAM-B protein involvement 
in the control of cellular motility and formation of cellular 
projections in cancer cells, a number of researchers have 
focused on the roles of JAM-B and regulation of this molecule 
in cancer cells and tissues. Clinical studies have mentioned 
different expression profiles and roles of JAM-B in various 
types of cancers. The inconsistency of the results in different 
cancers has led to an uncertainty regarding the role of JAM-B 
in carcinogenesis. 
Tumor metastasis is the movement or spreading of tumor 
cells from the primary site to a distant one. Circulating tumor 
cells, separated from primary tumor, can interact with vascular 
endothelial cells during hematogenous metastatic dissemina-
tion. Metastatic and invasive potential of a tumor cell depends 
on the expression of various proteins at each step of the meta-
static cascade. Numerous studies showed JAM-B played an 
important role in the metastasis of tumor cells (57-59). 
JAM-B in gastric carcinoma. Gastric cancer, one of the 
most common malignancies, is the second leading cause of 
cancer-related death globally. Many patients who had gastric 
cancer previously could still suffer from tumor recurrence and 
Table II. Regulation of CCNs in cancer.
Tumor type  JAM-B expression level
Gastric carcinoma ↑
Colorectal cancer ↓
Glioma ↑
ESCC ↓
Breast Cancer ↑/↓
NSCLC ↓
OSCC ↑
RA ↓
ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell 
lung cancer; OSCC, oral squamous cell carcinoma; RA, rheumatoid 
arthritis. ↓: JAM-B is lower expressed in tumor tissue than in cor-
responding normal tissue; ↑: JAM-B is higher expressed in tumor 
tissue than in corresponding normal tissue; ↑/↓: JAM-B expression 
in tumor is controversial. 
Table I. Classic JAM family: Tissue distribution and main functions.
 Cell expression  Tissue expression References
JAM-A Epithelial cells, endothelial cells, leukocytes,  Brain, heart, blood, bone marrow, intestine,  (2,24,81-87)
 platelets, spermatozoa/Sertoli cells, HSC kidney, liver, lung, pancreas, spleen,
  lymph node, skin, placenta, testis
JAM-B HEV, lymphatics, Sertoli cells, HSC, NSC Heart, placenta, testis, kidney,  (18,36,38,46,78,88,89)
 vascular and lymphatic endothelial cells lymph nodes, intestine, brain,
  lymph node (HEV), skin, heart, lung
JAM-C Vascular and lymphatic endothelial cells, DC,  Brain, bone marrow, heart, smooth muscle, (18,36,86,88,89)
 Pl, NK, HEV, lymphatics, platelets, spermatid,  uterus, lung, liver, kidney, spleen, testis,
 HSC, Schwann cells, fibroblast,  nerve, lymph node (HEV), skin, 
 leukocytes (human) cornea, placenta, testis
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metastasis following curative gastrectomy. Deregulation of 
the expression and function of TJ proteins leads to the initia-
tion and progression of cancer by activation of cytoskeleton 
mechanism. Hajjari et al examined the changes in expression 
levels of genes encoding tight junction-associated proteins of 
JAM-B and JAM-C in gastric adenocarcinoma in comparison 
with their corresponding marginal normal gastric tissues from 
the same patients. They found that JAM-B was upregulated 
significantly in tumor samples compared with adjacent normal 
tissues and was higher in high grade tumors than in the low 
grade and intermediate grade tumors. Moreover, they showed 
JAM-B and JAM-C activated the expression of actin filament-
associated protein (AFAP) gene as a downstream factor of 
JAM-B and JAM-C and this resulted in a significantly higher 
expression of AFAP (57). Recently, whole genome and tran-
scriptome sequencing in primary and peritoneal metastatic 
gastric carcinoma indicated JAM-B was only expressed in 
primary tumors (58). Overall, deregulation of JAM-B and 
JAM-C expression may potentially be involved in progression 
of gastric adenocarcinoma tumors. However, JAM-A was 
downregulated in gastric cancer tissues compared to adjacent 
non-tumor tissues from the same patients, and low JAM-A 
expression contributed to poor clinical outcome and increased 
cell invasion and migration in gastric cancer (59).
JAM-B in colorectal cancer. Recently, Kok-Sin et al studied 
150 colorectal tissues with the methylation-specific multi-
plex ligation-dependent probe amplification (MS-MLPA), 
and they found JAM-B was expressed at very low levels in 
colorectal cancer due to JAM-B genes being hypermethyl-
ated on promoters in CpG islands (60). The hypermethylation 
of the promoter and the downregulation of JAM-B in colon 
cancer were also supported by a report from 2011 (61). 
Another recent study showed the expression changes of 
cell-cell adhesion-related genes among 26 colorectal cancer, 
42 adenoma and 24 normal mucosa samples. Between these 
tissue types, different expression were observed in the mRNA 
levels of JAM-B genes encoding adherence junction proteins 
and JAM-B was expressed at lower levels in adenocarcinoma 
and adenoma than in normal colonic mucosa. Further, JAM-B 
has the lowest expression levels in adenoma (62).
JAM-B in glioma. Brain invasion is a biological hallmark of 
glioma which contributes to its aggressiveness and prognosis. 
Deregulated expression of JAMs in glioma cells has been 
implicated in this process. Recently, a study showed that 
JAM-B was aberrantly expressed in glioma as a high affinity 
JAM-C ligand. The interaction of JAM-B and JAM-C could 
activate c-Src proto-oncogene, which is known as a central 
upstream molecule in the pathways regulating cell invasion 
and migration. Also it was shown that JAM-B/C blocking 
antibodies impaired in vivo glioma invasion and proliferation 
in mice (63). Magnetic nanoparticle mediated JAM-2 silencing 
also inhibited the growth and migration of glioma in vitro and 
in vivo (64). A similar study from the same laboratory also 
found that the silencing of JAM-2 by proton-sponge coated 
quantum dots inhibited the migration of glioma in vitro 
through NOTCH pathway blockage (65). In short, targeting of 
the JAMs family may provide a potential lead for the treatment 
of human gliomas.
JAM-B in melanoma. Melanoma is the most dangerous type of 
skin cancer. Many factors have been proposed to influence the 
metastasis of melanoma in patients. Arcangeli et al indicted 
JAM-B expressed by endothelial cells was involved in mela-
noma cell metastasis via its interaction with JAM-C on tumor 
cells. Furthermore, using a JAM-B-deficient mouse model, it 
was found that the differential migration disappeared between 
JAM-C expressing cells and JAM-C silenced cells, revealing 
that JAM-B acted as a counter-receptor for JAM-C mediated 
reservation of melanoma cells in the lungs (66).
JAM-B in esophageal squamous cell carcinoma (ESCC). 
Esophageal squamous cell carcinoma is an aggressive and 
malignant tumor for which there is limited treatment option. 
The reason for this is that most cases are diagnosed late, and 
patients are already in the advanced stages of the disease. 
Lymph node metastasis often arises from this type of cancer, 
due to the rich lymphatic drainage system in the esophagus. 
Recently, it was demonstrated that the methylation of JAM-B 
was increased in the region downstream of the gene and its 
expression was decreased (67). Furthermore, a similar result 
showed that the expression JAM-B was downregulated and 
JAM-B was identified as a key player in the signal transduction 
networks in ESCC (68).
JAM-B in breast cancer. In females, breast cancer is the 
leading cancer with high incidence and frequently diagnosed 
malignancy, with lower survival rates in patients. JAM-B 
is a necessary component of apical junctional compo-
nents. Recently, Coradini et al reported that mutant p53 
tumors of breast cancer were characterized by a dramatic 
under-expression of several genes coding for apical junctional 
components (69). Further, a report from Bhan et al stated that 
JAM-B was associated with breast cancer progression (70). 
In 2010, our laboratory showed JAM-B had a significantly 
lower level in breast tumors from patients who developed 
metastasis than those who were disease-free. We concluded 
that JAM-B decreased migration and metastasis of breast 
cancer cells. In contrast, JAM-A expression was upregulated 
in breast cancer tissues compared to the normal specimen and 
was correlated to reduced survival of breast tumor patients, 
thus JAM-A overexpression could be a possible mechanism 
promoting breast cancer cell migration (71). 
JAM-B in lung cancer. Lung cancer is a malignant lung tumor 
characterized by uncontrolled cell proliferation in tissues of the 
lung. JAM-2 was negatively expressed in normal mouse lung, 
but positively expressed in spleen and lymph nodes surrounding 
the lung (72). An interesting discovery showed that overex-
pression of JAM-B in a trisomy-21 mouse model of Down's 
syndrome was responsible for inhibiting VEGF-induced angio-
genesis and, thus, restraining tumor effects in a lung carcinoma 
mouse model (73). Conversely, the expression level of JAM-A 
in lung tumor tissues was higher than corresponding normal 
lung tissues and served as a negative predictor of survival in 
lung cancer patients. Thus, JAM-A contributes to lung cell 
growth through cell cycle regulation (74).
JAM-B in oral squamous cell carcinoma. Oral squamous cell 
carcinoma (OSCC) characteristically metastasizes from the 
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primary organ to regional lymph nodes in the early stages of 
the cancer. It was demonstrated that JAM-B correlated with 
the metastatic potential, as it was upregulated in human oral 
cancer LNM Tca8113 cells which metastasized to lymph 
nodes at an higher rate than its parental cell line Tca8113 (75). 
Therefore it was suggested JAM-B acts as a potential factor for 
the metastasis of OSCC.
Role of JAM-B in other diseases. Zhang et al examined the 
relationship between JAM-B polymorphisms and the risk of 
rheumatoid arthritis (RA) among the Chinese population and 
excluded the affiliation between JAM-B polymorphisms and 
a decreased risk of RA (76). A study on inflammation indi-
cated JAM-B expression was restricted to the endothelium of 
arterioles in and adjacent to lymphocytic inflammation sites 
but was not discovered in liver specimens, signifying JAM-B 
may only be inducible in some inflammatory tissue types (11). 
Another similar study showed that JAM-B was involved in 
leukocyte extravasation to inflammation sites (49). Tumor 
angiogenesis is a fundamental step of cancer progression. 
Moreover, Meguenani et al reported that JAM-B interfered 
with angiogenic VEGF/VEGFR2 signaling which is a major 
pathway necessary for tumor angiogenesis, suggesting JAM-B 
could provide a useful possibility for the diagnosis and treat-
ment of relevant diseases (56). 
6. Conclusion 
Recent studies focusing on the interaction of JAMs 
have determined multiple homophilic and heterophilic 
cis/trans-interactions. Further, regulation of JAM functions 
arises by establishing intracellular/extracellular multi-
protein complexes. The family of JAMs shows stability in 
expression levels under various conditions, indicating a vital 
role under pathological and homeostatic conditions (42,77). 
JAMs also play an important role in decreasing epithelial 
paracellular permeability. An increasing number of studies 
has concentrated on the role of JAMs in tumors. It is clear 
that JAMs regulate cell growth, invasion and migration. 
Perturbed expression of JAMs has been observed in various 
malignancy types. The abnormal expression of certain 
JAMs is related to disease progression and poor prognosis. 
Different JAMs may play contrasting roles in the same 
cancer, while the same JAM may undertake converse roles 
in different tumor types.
7. Future perspectives
JAM-B interact with various receptors and cytokines to modu-
late downstream signal transduction. Most studies concerning 
JAM-B showed it does not assume a single role in regulating 
tumors, but always with JAM-C-dependence. JAM-B/-C is 
an important complex in cell-cell signaling. Its molecular 
mechanism of action is in need of further investigation. Many 
researchers have shown that JAM-B is an important regulator 
in various diseases. According to the above cited studies, 
the expression level of JAM-B is different in various tumors 
compared with normal tissues from the same patients. Thus, 
JAM-B may have different potentiality in the regulation of 
cancer metastasis. Further, insight into the detailed mecha-
nisms involved in JAM-B-mediated regulation would be useful 
in the understanding its function and role in tumorigenesis 
and tumor metastasis. Further investigations will highlight its 
clinical significance and application for predicting prognosis. 
In the future JAM-B may well provide preoperative diagnosis 
and a new avenue for targeted therapy in certain malignancies.
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